Live
FierceBiotechBeOne signs $2B deal for option on preclinical trispecific antibody from China’s HuahuiCytiva (Google News)Rockwell Automation and Cytiva launch Figurate SCADA system to eliminate digital bottlenecks in biopharmaceutical manufacturing - Manufacturing ChemistEndpoints NewsLack of specifics on obesity pill sales hover over Lilly’s first quarterEndpoints NewsThe R&D 15: How pharma's top companies spent, won and lost on drug researchEndpoints NewsNovartis unveils North Carolina factory as final new build in $23B US expansionFierceBiotechGSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 210x Genomics News10x Genomics Inc (HAM:1KJ) Stock Earnings Transcripts - GuruFocusFierceBiotechAvalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugsFierceBiotechAstraZeneca plucks preclinical EGFR degrader from Pinetree for $25MNovo NordiskIs Novo Nordisk's GLP-1 dominance fading after Lilly's clinical wins? - MSNSiemens HealthineersSiemens Healthineers: A €6 Billion Diagnostics Exit and a Coming Spin-Off as Shares Hit Rock Botto - AD HOC NEWSBioPharma DiveAvalyn, in pursuit of better lung drugs, banks $300M in an IPO
C.GERHARDT 10 févr. 2024

PERICYTES AS TARGETS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA - Frontiers

PERICYTES AS TARGETS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA - Frontiers

Original
Contenu indisponible. Consultez la source originale.